Clinical Trial Update: SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SB-715992 in patients with recurrent or metastatic head and neck cancer; the study completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Lip and Oral Cavity Cancer
• Oropharyngeal Cancer
• Paranasal Sinus and Nasal Cavity Cancer
• Salivary Gland Cancer

Drugs mentioned

• SB-715992

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED | Results posted: 2017-03-06